Skip to main content

Table 4 Odds ratios (95% confidence intervals (CI)) for a doubling of baseline sex hormone levels in the randomized placebo and active treatment groups of the Women’s Health Initiative postmenopausal hormone therapy trials

From: Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects

  Odds ratio (95% CI) Numbers of cases/controls
  Placebo Active  
CEE + MPA trial*
Estradiol 2.00 (1.24, 3.21) 0.96 (0.66, 1.40) 276/314
Bioavailable estradiol 1.98 (1.27, 3.07) 1.01 (0.72, 1.43) 265/299
Estrone 1.77 (1.15, 2.73) 1.07 (0.74, 1.56) 273/313
Estrone sulfate 1.18 (0.78, 1.80) 1.08 (0.78, 1.49) 245/287
SHBG* 0.75 (0.51, 1.12) 1.14 (0.82, 1.59) 274/323
CEE trial*
Estradiol 1.50 (0.85, 2.65) 1.31 (0.88, 1.97) 172/207
Bioavailable estradiol 1.69 (0.99, 2.87) 1.58 (1.06, 2.36) 169/203
Estrone 1.28 (0.78, 2.10) 1.31 (0.83, 2.07) 186/216
Estrone sulfate 1.58 (0.91, 2.73) 1.05 (0.65, 1.70) 160/184
SHBG* 0.65 (0.39, 1.08) 0.61 (0.40, 0.92) 178/208
  1. *CEE + MPA, conjugated equine estrogens plus medroxyprogesterone acetate; CEE, conjugated equine estrogens; SHBG, sex hormone binding globulin.